Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab biomarker discovery study in advanced urothelial cancer
NL-OMON53077Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in transitional cell carcinoma (TCC) and urinary tract cancer, sponsored by Erasmus MC. Started Aug 2017; status: active, not recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)urinary tract cancer
Beyond the preview
Go deeper on NL-OMON53077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53077.